Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils
Proceedings of the National Academy of Sciences · 2023
DOI: 10.1073/pnas.2300258120 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2023. Verfasst von Romany Abskharon und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA 90095. Hauptthemen laut MEDLINE: Alzheimer Disease, Single-Domain Antibodies, Supranuclear Palsy, Progressive. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Howard Hughes Medical Institute, NIA NIH HHS, NIGMS NIH HHS.
Themen: Demenz
Abstract (Originalsprache)
Despite much effort, antibody therapies for Alzheimer’s disease (AD) have shown limited efficacy. Challenges to the rational design of effective antibodies include the difficulty of achieving specific affinity to critical targets, poor expression, and antibody aggregation caused by buried charges and unstructured loops. To overcome these challenges, we grafted previously determined sequences of fibril-capping amyloid inhibitors onto a camel heavy chain antibody scaffold. These sequences were designed to cap fibrils of tau, known to form the neurofibrillary tangles of AD, thereby preventing fibril elongation. The nanobodies grafted with capping inhibitors blocked tau aggregation in biosensor cells seeded with postmortem brain extracts from AD and progressive supranuclear palsy (PSP) patients. The tau capping nanobody inhibitors also blocked seeding by recombinant tau oligomers. Another challenge to the design of effective antibodies is their poor blood–brain barrier (BBB) penetration. In this study, we also designed a bispecific nanobody composed of a nanobody that targets a receptor on the BBB and a tau capping nanobody inhibitor, conjoined by a flexible linker. We provide evidence that the bispecific nanobody improved BBB penetration over the tau capping inhibitor alone after intravenous administration in mice. Our results suggest that the design of synthetic antibodies that target sequences that drive protein aggregation may be a promising approach to inhibit the prion-like seeding of tau and other proteins involved in AD and related proteinopathies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry and Biochemistry, UCLA, Los Angeles, CA 90095.
- Department of Biological Chemistry, UCLA, Los Angeles, CA 90095.
- HHMI, UCLA, Los Angeles, CA 90095.
- UCLA-Department of Energy Institute, Molecular Biology Institute, UCLA, Los Angeles, CA 90095.
- Molecular Instrumentation Center, UCLA, Los Angeles, CA 90095.
- VIB-Vrije Universiteit Brussel Center for Structural Biology, VIB and Vrije Universiteit Brussel, Brussels B-1050, Belgium.
ORCID-Profile: Romany Abskharon, Hope Pan, Michael R Sawaya, Paul M Seidler, Eileen J Olivares, Yu Chen, Kevin A Murray, Megan Bentzel, David R Boyer, Duilio Cascio, Ke Hou, Els Pardon, Lea T Grinberg, William W Seeley, Jan Steyaert, Charles G Glabe, Rachel R Ogorzalek Loo, Joseph A Loo, David S Eisenberg
Förderung
- Howard Hughes Medical Institute
- NIA NIH HHS
- NIGMS NIH HHS
- NINDS NIH HHS
- NCRR NIH HHS
- HHS | NIH | National Institute on Aging
- HHS | NIH | National Institute of Neurological Disorders and Stroke
- BrightFocus Foundation
Zitieren
APA
Abskharon, R., Pan, H., Sawaya, M. R., Seidler, P. M., Olivares, E. J., Chen, Y., Murray, K. A., Zhang, J., Lantz, C., Bentzel, M., Boyer, D. R., Cascio, D., Nguyen, B. A., Hou, K., Cheng, X., Pardon, E., Williams, C. K., Nana, A. L., Vinters, H. V., …, & Eisenberg, D. S. (2023). Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2300258120
Vancouver
Abskharon R, Pan H, Sawaya MR, Seidler PM, Olivares EJ, Chen Y, et al. Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils. Proceedings of the National Academy of Sciences. 2023. doi:10.1073/pnas.2300258120
BibTeX
@article{Abskharon2023,
author = {Abskharon, Romany and Pan, Hope and Sawaya, Michael R and Seidler, Paul M and Olivares, Eileen J and Chen, Yu and Murray, Kevin A and Zhang, Jeffrey and Lantz, Carter and Bentzel, Megan and Boyer, David R and Cascio, Duilio and Nguyen, Binh A and Hou, Ke and Cheng, Xinyi and Pardon, Els and Williams, Christopher K and Nana, Alissa L and Vinters, Harry V and Spina, Salvatore and Grinberg, Lea T and Seeley, William W and Steyaert, Jan and Glabe, Charles G and Ogorzalek Loo, Rachel R and Loo, Joseph A and Eisenberg, David S},
title = {Structure-based design of nanobodies that inhibit seeding of Alzheimer’s patient–extracted tau fibrils},
journal = {Proceedings of the National Academy of Sciences},
year = {2023},
doi = {10.1073/pnas.2300258120}
}
EUVIMED